Camrelizumab with carboplatin and nab-paclitaxel shows potential as a first-line treatment for ES-SCLC, with promising survival rates. The study identified biomarkers, including MUC17 alterations and ...
Please provide your email address to receive an email when new articles are posted on . Survival outcomes did not differ for patients with HNSCC who received radiotherapy with carboplatin-paclitaxel ...
TTCC-2022-01: Niraparib and dostarlimab in locally-advanced head and neck squamous cell carcinoma treated with (chemo) radiotherapy (RADIAN). This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback